JP2019511442A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511442A5 JP2019511442A5 JP2018540795A JP2018540795A JP2019511442A5 JP 2019511442 A5 JP2019511442 A5 JP 2019511442A5 JP 2018540795 A JP2018540795 A JP 2018540795A JP 2018540795 A JP2018540795 A JP 2018540795A JP 2019511442 A5 JP2019511442 A5 JP 2019511442A5
- Authority
- JP
- Japan
- Prior art keywords
- carbon
- powder mixture
- carbon powder
- dots
- neutralized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 78
- 238000000034 method Methods 0.000 claims description 59
- 239000000203 mixture Substances 0.000 claims description 57
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 37
- 229910052799 carbon Inorganic materials 0.000 claims description 26
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 6
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- 238000002425 crystallisation Methods 0.000 claims description 6
- 230000008025 crystallization Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 230000003472 neutralizing effect Effects 0.000 claims description 6
- 150000002823 nitrates Chemical class 0.000 claims description 6
- 229910017604 nitric acid Inorganic materials 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 6
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- 102000004877 Insulin Human genes 0.000 claims description 4
- 108090001061 Insulin Proteins 0.000 claims description 4
- 102000004338 Transferrin Human genes 0.000 claims description 4
- 108090000901 Transferrin Proteins 0.000 claims description 4
- 230000008499 blood brain barrier function Effects 0.000 claims description 4
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 239000013078 crystal Substances 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- 229940125396 insulin Drugs 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 150000002894 organic compounds Chemical class 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000012581 transferrin Substances 0.000 claims description 4
- 239000012466 permeate Substances 0.000 claims description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 206010061592 cardiac fibrillation Diseases 0.000 claims description 2
- 230000001268 conjugating effect Effects 0.000 claims description 2
- 239000008367 deionised water Substances 0.000 claims description 2
- 229910021641 deionized water Inorganic materials 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 230000002600 fibrillogenic effect Effects 0.000 claims description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 239000011858 nanopowder Substances 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 239000013557 residual solvent Substances 0.000 claims description 2
- 239000004576 sand Substances 0.000 claims description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 2
- 235000011152 sodium sulphate Nutrition 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 230000003381 solubilizing effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022133069A JP7442854B2 (ja) | 2016-02-05 | 2022-08-24 | 診断分析及び薬物送達のためのカーボンドット |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662292026P | 2016-02-05 | 2016-02-05 | |
| US62/292,026 | 2016-02-05 | ||
| PCT/US2017/016743 WO2017136846A1 (en) | 2016-02-05 | 2017-02-06 | Carbon dots for diagnostic analysis and drug delivery |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022133069A Division JP7442854B2 (ja) | 2016-02-05 | 2022-08-24 | 診断分析及び薬物送達のためのカーボンドット |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511442A JP2019511442A (ja) | 2019-04-25 |
| JP2019511442A5 true JP2019511442A5 (cg-RX-API-DMAC7.html) | 2020-03-19 |
| JP7134484B2 JP7134484B2 (ja) | 2022-09-12 |
Family
ID=59500946
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018540795A Active JP7134484B2 (ja) | 2016-02-05 | 2017-02-06 | 診断分析及び薬物送達のためのカーボンドット |
| JP2022133069A Active JP7442854B2 (ja) | 2016-02-05 | 2022-08-24 | 診断分析及び薬物送達のためのカーボンドット |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022133069A Active JP7442854B2 (ja) | 2016-02-05 | 2022-08-24 | 診断分析及び薬物送達のためのカーボンドット |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20180362344A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3411330B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7134484B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN109071227B (cg-RX-API-DMAC7.html) |
| CA (1) | CA3013625C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017136846A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7266800B2 (ja) * | 2018-07-06 | 2023-05-01 | バイオグラフェン インコーポレイテッド | 神経タンパク質の異常な線維化または凝集に関連する疾患治療剤としてのグラフェン量子ドット |
| CN110639019B (zh) * | 2019-09-20 | 2022-10-11 | 湖北大学 | 基于碳点和中空二氧化锰的荧光共振能量转移的药物载体系统 |
| CN110791290A (zh) * | 2019-10-22 | 2020-02-14 | 长春师范大学 | 一种长余辉材料的制备方法 |
| CN111184875A (zh) * | 2019-12-16 | 2020-05-22 | 中国科学院理化技术研究所 | 一种蛋白质/碳点纳米杂化材料及其制备方法和应用 |
| CN113548656B (zh) * | 2020-06-16 | 2023-02-21 | 哈尔滨成程生命与物质研究所 | 一种具有抗癌生物活性的碳点及制备方法 |
| CN112158826B (zh) * | 2020-10-12 | 2023-03-21 | 中国人民解放军总医院第五医学中心 | 一种碳点纳米制剂及其制备方法和应用 |
| CN113549450B (zh) * | 2021-07-28 | 2022-05-31 | 山西大学 | 一种基于火轮果皮的钾氮共掺杂碳点及其制备方法和应用 |
| CN115285975B (zh) * | 2022-08-25 | 2024-03-12 | 山西大学 | 一种可用于环丙沙星快速检测的两亲性碳点的制备方法 |
| JPWO2024057464A1 (cg-RX-API-DMAC7.html) | 2022-09-14 | 2024-03-21 | ||
| CN116120917A (zh) * | 2023-01-12 | 2023-05-16 | 澳门大学 | 碳纳米点复合氨基酸试剂及其制备方法和应用 |
| CN116077559B (zh) * | 2023-04-10 | 2023-06-20 | 中国农业大学 | 一种仙鹤草碳点及其制备方法和应用 |
| CN117185281A (zh) * | 2023-08-01 | 2023-12-08 | 哈尔滨工业大学 | 可定量评价骨靶向性能的碳点、基于链转移一步法合成它的方法以及评价方法和应用 |
| CN117430974A (zh) * | 2023-10-30 | 2024-01-23 | 兰溪博观循环科技有限公司 | 碳黑的处理工艺 |
| CN117819536B (zh) * | 2023-12-22 | 2026-04-21 | 北京师范大学 | 一种水溶性肿瘤靶向碳点及其制备方法和应用 |
| CN118206108B (zh) * | 2024-03-20 | 2026-06-23 | 上海大学 | 一种蓝色荧光碳量子点及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2447395A1 (en) * | 2001-05-16 | 2002-11-21 | Faulk Pharmaceuticals, Inc. | Targeted delivery of drugs for the treatment of parasitic infections |
| US7767185B2 (en) * | 2003-09-30 | 2010-08-03 | Nec Corporation | Method of producing a carbon nanotube and a carbon nanotube structure |
| TWI429460B (zh) * | 2011-12-19 | 2014-03-11 | Ind Tech Res Inst | 抗凝血劑共軛之奈米碳球、含其之抗血栓劑及其製造方法 |
| WO2016053411A1 (en) * | 2014-06-19 | 2016-04-07 | William Marsh Rice University | Bandgap engineering of carbon quantum dots |
| JP2016525997A (ja) * | 2013-05-02 | 2016-09-01 | ウィリアム・マーシュ・ライス・ユニバーシティ | 石炭とコークスからグラフェン量子ドットを生成する方法 |
| EP3068442B1 (en) | 2013-11-14 | 2026-03-25 | The Royal Institution for the Advancement of Learning / McGill University | Bionanofluid for use as a contrast, imaging, disinfecting and/or therapeutic agent |
| JP6316011B2 (ja) * | 2014-02-04 | 2018-04-25 | 国立大学法人滋賀医科大学 | 抗癌剤が担持されたナノ粒子 |
| KR20160003488A (ko) * | 2014-07-01 | 2016-01-11 | 포항공과대학교 산학협력단 | 히알루론산-탄소나노물질 결합체 및 이를 포함하는 광역학 치료용 조성물 |
| AP2017009797A0 (en) * | 2014-08-08 | 2017-03-31 | Olanrewaju W Tanimola | Methods for synthesis of graphene derivatives and functional materials from asphaltenes, graphene derivatives, 2d materials and applications of use |
| CA2966994A1 (en) * | 2014-11-06 | 2016-07-28 | William Marsh Rice University | Methods of making graphene quantum dots from various carbon sources |
| CN104987862B (zh) * | 2015-06-23 | 2017-03-08 | 西南大学 | 具有持续高尔基体靶向成像能力的碳点及其制备方法 |
-
2017
- 2017-02-06 CA CA3013625A patent/CA3013625C/en active Active
- 2017-02-06 WO PCT/US2017/016743 patent/WO2017136846A1/en not_active Ceased
- 2017-02-06 JP JP2018540795A patent/JP7134484B2/ja active Active
- 2017-02-06 CN CN201780021414.4A patent/CN109071227B/zh active Active
- 2017-02-06 EP EP17748361.7A patent/EP3411330B1/en active Active
- 2017-02-06 CN CN202211421507.5A patent/CN115998889A/zh active Pending
-
2018
- 2018-08-03 US US16/054,166 patent/US20180362344A1/en not_active Abandoned
-
2022
- 2022-08-24 JP JP2022133069A patent/JP7442854B2/ja active Active
- 2022-11-22 US US17/992,783 patent/US20230087420A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023201651B2 (en) | Encapsulation of messenger rna | |
| CN109071227B (zh) | 用于诊断分析和药物递送的碳量子点 | |
| RU2746406C2 (ru) | Вакцины на основе нуклеиновых кислот | |
| CN113271926A (zh) | 脂质纳米颗粒的制备及其施用方法 | |
| WO2023067123A1 (en) | Oligosaccharide complexes and uses | |
| JP2022532213A (ja) | Mrna担持脂質ナノ粒子を調製する改善されたプロセス | |
| RU2738374C1 (ru) | Натриевая соль 5-бром-2-(альфа-гидроксипентил)бензойной кислоты | |
| Wang et al. | Synergic treatment of Alzheimer’s disease with brain targeted nanoparticles incorporating NgR-siRNA and brain derived neurotrophic factor | |
| EP3305305A2 (en) | Silicate containing compositions and methods of treatment | |
| RU2017126093A (ru) | Продукты для доставки терапевтических/диагностических соединений к сердцу | |
| CN112206315A (zh) | 转铁蛋白、及其联合甘露特钠胶囊的应用以及包含甘露特钠胶囊的组合物 | |
| CN108947959B (zh) | 一种非离子型碘造影剂中间体的制备方法 | |
| WO2023072890A1 (en) | Process for the preparation of sucrose octasulfate octakistriethylammonium salt (tasos) powder and uses thereof | |
| JP2021529787A5 (cg-RX-API-DMAC7.html) | ||
| JP6126102B2 (ja) | 純粋なS−(−)−9−フルオロ−6,7−ジヒドロ−8−(4−ヒドロキシピペリジン−1−イル)−5−メチル−1−オキソ−1H,5H−ベンゾ[i,j]キノリジン−2−カルボン酸L−アルギニン塩4水和物およびその製造方法 | |
| CN111689956B (zh) | 一种含有季铵基团的奎宁类化合物的拆分方法 | |
| EP4605010A1 (en) | Nucleic acid complexes and uses thereof | |
| CN101844811A (zh) | 抗肝炎病毒的铌钨酸盐化合物 | |
| CN109528638B (zh) | 利巴韦林衍生物制剂及其制备方法 | |
| RU2240803C1 (ru) | Способ получения водного раствора для инфузий | |
| WO2025262672A1 (en) | Lipid compositions for nucleic acid delivery | |
| KR20260016938A (ko) | 무적재율이 낮은 핵산 지질 나노입자 및 그에 대한 제조 방법 | |
| JP2014189552A (ja) | グリセロリン酸塩の製造方法 | |
| ITBO20080224A1 (it) | Microbolle di alcol polivinilico atte al rilascio di no | |
| CN106110328A (zh) | 一种利用磷酸钙沉淀辅助提高布洛芬在水中溶解度的方法 |